Back to Search
Start Over
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies
- Source :
- Cancer. 122:2178-2185
- Publication Year :
- 2016
- Publisher :
- Wiley, 2016.
-
Abstract
- BACKGROUND Older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) are reported to have a poor prognosis and few therapeutic options. In the current study, the authors evaluated treatment with single-agent blinatumomab in adults aged ≥65 years with r/r ALL. METHODS A total of 261 adults with r/r ALL who were examined across two phase 2 studies received blinatumomab in cycles of 4-week continuous infusion and 2-week treatment-free intervals. The primary endpoint in each study was complete remission (CR) or CR with partial hematologic recovery (CRh) during the first 2 cycles. Data were pooled and analyzed according to patient age at screening (aged ≥65 years vs aged
- Subjects :
- Cancer Research
medicine.medical_specialty
business.industry
Incidence (epidemiology)
medicine.medical_treatment
Hematopoietic stem cell transplantation
Minimal residual disease
Hematologic Response
Confidence interval
Surgery
03 medical and health sciences
0302 clinical medicine
Oncology
030220 oncology & carcinogenesis
Internal medicine
medicine
Clinical endpoint
Blinatumomab
Adverse effect
business
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 0008543X
- Volume :
- 122
- Database :
- OpenAIRE
- Journal :
- Cancer
- Accession number :
- edsair.doi...........745a05963ed9fff75923c3eafc74ed42